

NCT00461136 Processed comparison:

Summary:
CHIA has 45 criteria while your personal folder has 60 criteria
Total found criteria: 39/45
Total not Found: 6/45
Total Extra: 15
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and/or female patients from 30-80 years of    │ Female patient from 30-80 years of age with a      │
│ age with a diagnosis of Type 2 diabetes (WHO       │ diagnosis of Type 2 diabetes (WHO criteria)        │
│ criteria)                                          │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Incipient and established diabetic nephropathy     │ Incipient diabetic nephropathy (urinary albumin    │
│ (urinary albumin excretion ≥ 100 mg/day but ≤ 2000 │ excretion ≥ 100 mg/day but ≤ 2000 mg/day)          │
│ mg/day)                                            │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Glomerular filtration rate (GFR) ≥ 40 ml/min       │ Glomerular filtration rate (GFR) ≥ 40 ml/min       │
│ (estimated using Modification of Diet in Renal     │ (estimated using Modification of Diet in Renal     │
│ Disease (MDRD) formula) in the last 4 months       │ Disease (MDRD) formula) in the last 4 months       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients must be on stable hypoglycemic            │ Patient must be on stable hypoglycemic medications │
│ medications for at least 8 weeks prior to Visit 2  │ for at least 8 weeks prior to Visit 2 (Day -1)     │
│ ( Day -1)                                          │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients must be willing and medically able to     │ Patient must be willing and medically able to      │
│ discontinue all Angiotensin-converting enzyme      │ discontinue all Angiotensin-converting enzyme      │
│ inhibitor (ACEI) Angiotensin receptor blocker      │ inhibitor (ACEI) Angiotensin receptor blocker      │
│ (ARB) aldosterone receptor antagonist and          │ (ARB) aldosterone receptor antagonist and          │
│ potassium sparing diuretic medications for the     │ potassium sparing diuretic medications for the     │
│ duration of the study                              │ duration of the study                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Oral body temperature within the range 35 0-37 5   │ Oral body temperature within the range 35 0-37 5   │
│ °C                                                 │ °C                                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to provide written informed consent prior to  │ Able to provide written informed consent prior to  │
│ study participation                                │ study participation                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to communicate well with the investigator and │ Able to communicate well with the investigator and │
│ comply with the requirements of the study          │ comply with the requirements of the study          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe Hypertension Grade 3 WHO classification     │ Severe Hypertension Grade 3 WHO classification     │
│ (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 │ (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 │
│ mmHg and/or Mean Sitting Systolic Blood Pressure   │ mmHg and/or Mean Sitting Systolic Blood Pressure   │
│ MSSBP 180 mmHg)                                    │ MSSBP 180 mmHg)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acetylsalicyclic acid (ASA) treatment >1g/day or   │ Acetylsalicyclic acid (ASA) treatment >1g/day or   │
│ regular use of Non steroidal anti-inflammatory     │ regular use of Non steroidal anti-inflammatory     │
│ drug (NSAIDs)                                      │ drug (NSAIDs)                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Kidney disease not caused by diabetes or           │ Kidney disease not caused by diabetes or           │
│ hypertension                                       │ hypertension                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum potassium < 3 5 or > 5 1 mEq/L               │ Serum potassium < 3 5 or > 5 1 mEq/L               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ GFR < 40 ml/min/1 73m2 as measured by the MDRD     │ GFR < 40 ml/min/1 73m2 as measured by the MDRD     │
│ formula                                            │ formula                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum albumin < 2 0mg/dL                           │ Serum albumin < 2 0mg/dL                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypertensive encephalopathy or          │ History of hypertensive encephalopathy or          │
│ cerebrovascular accident at any time prior to      │ cerebrovascular accident at any time prior to      │
│ Visit1                                             │ Visit 1                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current diagnosis of heart failure (New York Heart │ Current diagnosis of heart failure (New York Heart │
│ Association (NYHA) Class II-IV)                    │ Association (NYHA) Class II-IV)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of myocardial infarction unstable angina   │ History of myocardial infarction unstable angina   │
│ pectoris coronary bypass surgery or any            │ pectoris coronary bypass surgery or any            │
│ percutaneous coronary intervention (PCI) during    │ percutaneous coronary intervention (PCI) during    │
│ the 6 months prior to Visit 1                      │ the 6 months prior to Visit 1                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Second or third degree heart block without a       │ Second or third degree heart block without a       │
│ pacemaker                                          │ pacemaker                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent potentially life threatening arrhythmia │ Concurrent potentially life threatening arrhythmia │
│ or symptomatic arrhythmia                          │ or symptomatic arrhythmia                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant valvular heart disease      │ Clinically significant valvular heart disease      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Type 1 diabetes mellitus                           │ Type 1 diabetes mellitus                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled Type II diabetes mellitus (Hemaglobin │ Uncontrolled Type II diabetes mellitus (Hemaglobin │
│ subtype A1C (HbA1C) >11 %)                         │ subtype A1C (HbA1C) >11 %)                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignancy including leukemia and       │ History of malignancy including leukemia and       │
│ lymphoma (but not basal cell skin carcinoma)       │ lymphoma (but not basal cell skin carcinoma)       │
│ within the past five years                         │ within the past five years                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in any clinical investigation within │ Participation in any clinical investigation within │
│ 4 weeks prior to dosing or longer if required by   │ 4 weeks prior to dosing or longer if required by   │
│ local regulation                                   │ local regulation                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Donation or loss of 400 mL or more of blood within │ Donation or loss of 400 mL or more of blood within │
│ 8 weeks prior to dosing                            │ 8 weeks prior to dosing                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant illness within the two weeks prior to  │ Significant illness within the two weeks prior to  │
│ dosing                                             │ dosing                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of major gastrointestinal tract surgery    │ History of major gastrointestinal tract surgery    │
│ such as gastrectomy gastroenterostomy or bowel     │ such as gastrectomy gastroenterostomy or bowel     │
│ resection                                          │ resection                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current treatment with cholestyramine or           │ Current treatment with cholestyramine or           │
│ cholestipol resins                                 │ cholestipol resins                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of immunocompromise including a positive   │ History of immunocompromise including a positive   │
│ HIV test result                                    │ HIV test result                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of a positive Hepatitis B surface antigen  │ History of a positive Hepatitis B surface antigen  │
│ (HBsAg) or Hepatitis C test result                 │ (HBsAg) or Hepatitis C test result                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of drug or alcohol abuse within the 12     │ History of drug or alcohol abuse within the 12     │
│ months prior to dosing                             │ months prior to dosing                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Persons directly involved in the execution of this │ Persons directly involved in the execution of this │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any condition that in the opinion of the           │ Any condition that in the opinion of the           │
│ investigator or the Novartis medical monitor would │ investigator or the Novartis medical monitor would │
│ jeopardize the evaluation of efficacy or safety    │ jeopardize the evaluation of efficacy or safety    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of noncompliance to medical regimens or    │ History of noncompliance to medical regimens or    │
│ unwillingness to comply with the study protocol    │ unwillingness to comply with the study protocol    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known or suspected contraindications to the study  │ Known or suspected contraindications to the study  │
│ medications including history of allergy to        │ medications including history of allergy to        │
│ Angiotensin converting enzyme (ACE) inhibitors     │ Angiotensin converting enzyme (ACE) inhibitors     │
│ and/or to thiazide diuretics or other sulfonamide  │ and/or to thiazide diuretics or other sulfonamide  │
│ derived drug                                       │ derived drug                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any surgical or medical condition which in the     │ Any surgical or medical condition which in the     │
│ opinion of the investigator may place the patient  │ opinion of the investigator may place the patient  │
│ at higher risk from his/her participation in the   │ at higher risk from his/her participation in the   │
│ study or is likely to prevent the patient from     │ study or is likely to prevent the patient from     │
│ complying with the requirements of the study or    │ complying with the requirements of the study or    │
│ completing the study                               │ completing the study                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any prescription drug or over-the-counter   │ Use of any prescription drug or over-the-counter   │
│ (OTC) medication which is prohibited by the        │ (OTC) medication which is prohibited by the        │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who previously participated in any        │ Patients who previously participated in any        │
│ Aliskiren study                                    │ Aliskiren study                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or nursing woman                          │ Pregnant or nursing woman                          │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Female patients must be postmenopausal or must have had a bilateral oophorectomy or must have been   │
│ surgically sterilized or hysterectomized at least 6 months prior to screening                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ To be eligible patients must fulfill the following criteria Patients on ongoing hypertensive therapy │
│ must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1) AND      │
│ patients must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day  │
│ -1) Newly diagnosed hypertensive patients must have a blood pressure ≥ 135/85 mm Hg but lower than   │
│ 170/105 mm Hg at baseline (Day -1)                                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Any surgical or medical condition which might significantly alter the absorption distribution        │
│ metabolism or excretion of study drugs including but not limited to any of the following             │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ -Currently active or previously active inflammatory bowel disease during the 12 months prior to      │
│ Visit 1 Currently active gastritis duodenal or gastric ulcers or gastrointestinal/rectal bleeding    │
│ during the 3 months prior to Visit 1                                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Any history of pancreatic injury pancreatitis or evidence of impaired pancreatic function/injury as  │
│ indicated by abnormal lipase or amylase Evidence of hepatic disease a history of hepatic             │
│ encephalopathy a history of esophageal varices or a history of portocaval shunt                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Other protocol-defined inclusion/exclusion criteria may apply                                        │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Evidence of hepatic disease a history of hepatic encephalopathy a history of esophageal varices or a │
│ history of portocaval shunt                                                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Established diabetic nephropathy (urinary albumin excretion ≥ 100 mg/day but ≤ 2000 mg/day)          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day   │
│ -1)                                                                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female patient must have been hysterectomized at least 6 months prior to screening                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Male patient from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria)              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Currently active gastritis duodenal or gastric ulcers or gastrointestinal/rectal bleeding during the │
│ 3 months prior to Visit 1                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit │
│ 1                                                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Maximum age of 80 Years                                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female patient must have been surgically sterilized at least 6 months prior to screening             │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Any history of pancreatic injury pancreatitis or evidence of impaired pancreatic function/injury as  │
│ indicated by abnormal lipase or amylase                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient on ongoing hypertensive therapy must have a blood pressure ≥ 135/85 mm Hg but lower than     │
│ 170/105 mm Hg at baseline (Day -1)                                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female patient must be postmenopausal                                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female patient must have had a bilateral oophorectomy at least 6 months prior to screening           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Minimum age of 30 Years                                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Newly diagnosed hypertensive patient must have a blood pressure ≥ 135/85 mm Hg but lower than        │
│ 170/105 mm Hg at baseline (Day -1)                                                                   │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛